跳至主要内容
临床试验/NCT02795871
NCT02795871已完成不适用

Multicentric Evaluation of in Utero Dexamethasone (DEX) on the Cognitive Development of Children at Risk of Congenital Adrenal Hyperplasia

Hospices Civils de Lyon11 个研究点 分布在 1 个国家目标入组 354 人开始时间: 2016年10月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
354
试验地点
11
主要终点
Intelligence quotient

研究概览

简要总结

The classic form of 21-hydroxylase deficiency (prevalence 1/15,000) is the most common cause of congenital adrenal hyperplasia (CAH). This autosomic recessive disease is responsible for virilization of the external genitalia in girls through androgen hypersecretion during fetal life. Since 1984, the Lyon Pediatric Endocrinology group has proposed prenatal dexamethasone (DEX) for all fetuses at risk of CAH With the aim of preventing fetal androgen hypersecretion in affected girls and avoiding poor long-term results from reconstructive surgery. Prenatal DEX was used in Europe and the USA but its use was recently suspended: in 2007, a Swedish study conducted on 26 children treated with DEX in utero for a short period of time reported cognitive impairments. These data were not confirmed by an American study on the short-term DEX use, which showed potential cognitive impairments in CAH children exposed to DEX for long periods of time. These confusing and controversial results have caused the scientific community to question its position and have resulted in the suspension of the use of prenatal DEX with drastic consequences for CAH girls (virilization; genital surgery etc.). In this context, an evaluation of neuropsychological development under in utero DEX is essential to validate its indication for use during the prenatal period. This study will evaluate outcomes using prospective cognitive and emotional assessments. It will first focus on the unaffected children previously treated in utero in order to assess the adverse effects of the drug. The study will then assess the children with CAH for whom DEX could have beneficial effects.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
6 Years 至 15 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Groups D+1, D+2, D-1 and D-2
  • Male or female
  • Patient with Congenital Adrenal Hyperplasia or sibling of a CAH patient
  • Age: 6 to 15 years (at the time of inclusion)
  • The subject's legal representatives have understood the information note/informed consent form, obtained answers to all their questions and have given signed, written, informed consent
  • Subject with health insurance
  • Group D-3 (Schoolchildren)
  • Male or female
  • With no connection with Congenital Adrenal Hyperplasia
  • Age: 6 to 15 years (at the time of inclusion)
  • The subject's legal representatives have understood the information note/informed consent form, obtained answers to all their questions and have given signed, written, informed consent
  • Subject with health insurance

排除标准

  • For all groups :
  • Patient/Subject with another genetic disease
  • Patient/Subject with known neuropsychology disease(s)
  • Patient/Subject whose mother has received another treatment during her pregnancy with possible known adverse events on the neuropsychological development of the child

结局指标

主要结局

Intelligence quotient

时间窗: 3 months

Wechsler Intelligence Scale for Children (WISC) is designed to measure human intelligence. WISC-IV includes: * Verbal Comprehension Index: measure of verbal concept formation. * Perceptual Reasoning Index: measure of non-verbal and fluid reasoning. * Working Memory Index: measure of working memory. * Processing Speed Index: measure of processing speed. Data measured: raw score (0 to 150), standard score (1 to 19), index (40 to 160). The four indexes of the intelligence quotient will be considered hierarchically as follows: first the Working Memory Index, then the Processing Speed Index, third the Perceptual Reasoning Index, fourth the Verbal Comprehension Index.

次要结局

  • Children Memory Scale (CMS)(3 months)
  • Mood Depressive Inventory for Children (MDI- C) score(15 months)
  • Child Behavior Checklist (CBCL) score(15 months)
  • Evaluation of the benefits of in utero DEX in preventing or reducing the virilization of external genitalia in CAH girls(Day 1)
  • Rey figure test(3 months)
  • Revised - Child Measure of Anxiety Scale (R- CMAS) score(15 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验

进行中(未招募)
不适用
Multicentric evaluation of in utero dexamethasone (DEX) on the cognitive development of children at risk of Congenital Adrenal Hyperplasia - PRENATAL DEX StudyPatient with Congenital Adrenal Hyperplasia (CAH) or sibling of a CAH patient . Patient no connection with Congenital Adrenal HyperplasiaMedDRA version: 18.1Level: PTClassification code 10061630Term: Adrenogenital syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2015-003996-32-FRHospices Civils de Lyon
进行中(未招募)
1 期
Efficacy trial of two therapies in Menière´s disease
EUCTR2018-001958-10-ATAbteilung für Hals-, Nasen- und Ohrenkrankheiten MUW, AKH Wien20
已完成
不适用
Is there a difference between 2 doses of 12 mg of dexamethasone given 12 hours apart compared with 4 doses of 6 mg dexamethasone given 12 hours apart in terms of the dosing regimen's impact on causing high blood sugar in the mother when dexamethasone is given to minimise risk of prematurity complications?Women with mild gestational diabetes mellitus between 24-38 weeks receiving antenatal dexamethasone for improvement of neonatal outcome.Pregnancy and Childbirthmild gestational diabetes mellitus
ISRCTN16613220niversity Malaya60
已完成
3 期
The effect of dexamethasone in the treatment of high-risk covid19 patientsCOVID19.COVID-19, virus identifiedU07.1
IRCT20160118026097N4Ghoum University of Medical Sciences60
招募中
3 期
Effect of dexamethasone in patients with brain hemorrhage
CTRI/2023/04/051314AIIMS, New Delhi